JP2015517662A - 腫瘍細胞単離／精製方法およびそれの使用方法 - Google Patents

腫瘍細胞単離／精製方法およびそれの使用方法 Download PDF

Info

Publication number
JP2015517662A
JP2015517662A JP2015512640A JP2015512640A JP2015517662A JP 2015517662 A JP2015517662 A JP 2015517662A JP 2015512640 A JP2015512640 A JP 2015512640A JP 2015512640 A JP2015512640 A JP 2015512640A JP 2015517662 A JP2015517662 A JP 2015517662A
Authority
JP
Japan
Prior art keywords
cancer
drug candidate
cells
drug
candidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512640A
Other languages
English (en)
Japanese (ja)
Inventor
プレザント，キヤリー
ペレ，マシユー
ホールキスト，アラン
Original Assignee
ダイアテツク・オンコロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアテツク・オンコロジー filed Critical ダイアテツク・オンコロジー
Publication of JP2015517662A publication Critical patent/JP2015517662A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015512640A 2012-05-15 2013-03-14 腫瘍細胞単離／精製方法およびそれの使用方法 Pending JP2015517662A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647248P 2012-05-15 2012-05-15
US61/647,248 2012-05-15
PCT/US2013/031300 WO2013172955A1 (en) 2012-05-15 2013-03-14 Tumor cell isolation/purification process and methods for use thereof

Publications (1)

Publication Number Publication Date
JP2015517662A true JP2015517662A (ja) 2015-06-22

Family

ID=49584132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512640A Pending JP2015517662A (ja) 2012-05-15 2013-03-14 腫瘍細胞単離／精製方法およびそれの使用方法

Country Status (17)

Country Link
US (2) US20150160193A1 (enExample)
EP (1) EP2850434A4 (enExample)
JP (1) JP2015517662A (enExample)
KR (1) KR20150035537A (enExample)
CN (1) CN104704368A (enExample)
AU (1) AU2013263337A1 (enExample)
BR (1) BR112014028396A2 (enExample)
CA (1) CA2873180A1 (enExample)
CO (1) CO7240391A2 (enExample)
CR (1) CR20140575A (enExample)
HK (1) HK1208727A1 (enExample)
IL (1) IL235709A0 (enExample)
IN (1) IN2014DN09582A (enExample)
MX (1) MX2014013939A (enExample)
SG (1) SG11201407497TA (enExample)
TW (1) TW201409029A (enExample)
WO (1) WO2013172955A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12324657B2 (en) 2007-11-28 2025-06-10 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
EP2953544B1 (en) * 2013-02-06 2019-05-08 Intervet Inc. System for determining antibiotic effectiveness in respiratory diseased using auscultation analysis
MY189089A (en) 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN116327953A (zh) 2015-06-17 2023-06-27 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US20210011018A1 (en) * 2018-03-20 2021-01-14 Lumacyte, LLC Advanced biophysical and biochemical cellular monitoring and quantification using laser force cytology
TWI662130B (zh) * 2018-09-21 2019-06-11 國立臺灣大學 分離循環癌細胞之方法
CN111019899B (zh) * 2019-02-14 2023-08-04 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系lj-0429及其应用
CN111019897B (zh) * 2019-02-14 2023-08-11 中山大学孙逸仙纪念医院 人良性叶状肿瘤细胞系glk-1010及其应用
CN111019898B (zh) * 2019-02-14 2023-07-21 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系hjp-0320及其应用
CN113466417B (zh) * 2021-05-13 2023-03-21 柳州东风容泰化工股份有限公司 一种氟尿嘧啶的制备纯度评估方法及系统
WO2024054627A1 (en) * 2022-09-08 2024-03-14 The University Of North Carolina At Chapel Hill Diagnosis of patient tumor tissue
CN115747290A (zh) * 2022-11-23 2023-03-07 零壹人工智能科技研究院(南京)有限公司 一种对肠癌类器官进行药敏测试的新操作方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123103A1 (en) * 2010-03-31 2011-10-06 Diatech Oncology, Llc System and method for anti-cancer drug candidate evaluation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0891550A1 (en) * 1996-04-05 1999-01-20 The Johns Hopkins University School Of Medicine A method of enriching rare cells
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
WO2002040702A2 (en) * 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
KR100721927B1 (ko) * 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
IT1391619B1 (it) * 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123103A1 (en) * 2010-03-31 2011-10-06 Diatech Oncology, Llc System and method for anti-cancer drug candidate evaluation
JP2013523120A (ja) * 2010-03-31 2013-06-17 ダイアテツク・オンコロジー・エルエルシー 抗癌剤候補評価のためのシステムおよび方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BALLARD ET AL: "Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regim", JOURNAL OF GYNECOLOGIC ONCOLOGY, vol. 21, no. 1, JPN6016051059, March 2010 (2010-03-01), pages 45 - 49, ISSN: 0003474224 *

Also Published As

Publication number Publication date
WO2013172955A9 (en) 2014-02-27
SG11201407497TA (en) 2014-12-30
AU2013263337A1 (en) 2014-12-04
CR20140575A (es) 2015-05-07
CO7240391A2 (es) 2015-04-17
BR112014028396A2 (pt) 2018-05-29
TW201409029A (zh) 2014-03-01
EP2850434A4 (en) 2016-01-13
CA2873180A1 (en) 2013-11-21
WO2013172955A1 (en) 2013-11-21
US20170336391A1 (en) 2017-11-23
CN104704368A (zh) 2015-06-10
HK1208727A1 (zh) 2016-03-11
MX2014013939A (es) 2015-05-11
IN2014DN09582A (enExample) 2015-07-17
EP2850434A1 (en) 2015-03-25
US20150160193A1 (en) 2015-06-11
IL235709A0 (en) 2015-01-29
KR20150035537A (ko) 2015-04-06

Similar Documents

Publication Publication Date Title
JP2015517662A (ja) 腫瘍細胞単離／精製方法およびそれの使用方法
JP6787976B2 (ja) 細胞全体でのアッセイおよび方法
JP6782698B2 (ja) がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
CN109563486A (zh) 用于在癌症护理中做出患者特定的治疗决策的诊断方法
Kamińska et al. Liquid biopsy in melanoma: significance in diagnostics, prediction and treatment monitoring
US20230184744A1 (en) INTERTUMORAL HOMOGENEITY DETERMINED BY MiCK ASSAY
Tinhofer et al. Circulating tumor cells as biomarkers in head and neck cancer: recent advances and future outlook
Rahman et al. KRAS and MAPK1 gene amplification in type II ovarian carcinomas
Hu et al. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer
US20210318310A1 (en) Methods for monitoring polymorphonuclear myeloid derived suppressor cells
Vanegas et al. Leukemia-Induced cellular senescence and stemness alterations in mesenchymal stem cells are reversible upon withdrawal of B-cell acute lymphoblastic leukemia cells
Yin et al. Liquid biopsies in cancer
Mavrogenis et al. Biopsy techniques for musculoskeletal tumors: basic principles and specialized techniques
Zafar et al. Emerging biomarkers for early cancer detection and diagnosis: Challenges, innovations, and clinical perspectives
Soper et al. Cancer: a global concern that demands new detection technologies
Gao et al. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway
Hussain et al. Tumor-educated platelets in lung cancer
Liao et al. The microRNA-210-Stathmin1 axis decreases cell stiffness to facilitate the invasiveness of colorectal cancer stem cells
Gabriel et al. Association and regulation of protein factors of field effect in prostate tissues
Trombetta et al. Methylation analyses in liquid biopsy of lung cancer patients: A novel and intriguing approach against resistance to target therapies and immunotherapies
Kaira et al. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma
Xu et al. In silico screening applied in drug discovery: T001-10026247 as a novel fourth-generation EGFR inhibitor
Nykänen et al. Ex vivo drug screening informed targeted therapy for metastatic parotid squamous cell carcinoma
Choi et al. Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer
Li et al. Exosomal miRNA-188-3p derived from cancer-associated fibroblasts promotes ferroptosis in cervical cancer: Medical Biothermal Image Analysis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170802